Results 181 to 190 of about 30,927 (236)

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia. [PDF]

Discov Oncol
Hays P.
europepmc   +1 more source

Number needed to treat and associated cost analysis of zanubrutinib vs ibrutinib in chronic lymphocytic leukemia. [PDF]

J Manag Care Spec Pharm
Chanan-Khan A, Hanna K, Xue M, Massoudi M, Balk M, Gani R, Piran HZ, Yang K.   +7 more
europepmc   +1 more source

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis. [PDF]

Blood Adv
Shadman M, Brown JR, Mohseninejad L, Yang K, Burnett H, Neupane B, Williams R, Lamanna N, O'Brien SM, Tedeschi A, Tam CS.   +10 more
europepmc   +1 more source

The effect of ibrutinib on the myeloid cell compartment in CNS lymphoma. [PDF]

Leukemia
Kuehn JC, Neidert NN, Zhang J, Mutter J, Alig S, Klingler C, Hummel F, Ranganathan L, Bleul S, Beck J, Prinz M, Diehn M, Alizadeh A, Duyster J, Sankowski R, Heiland DH, Scherer F.   +16 more
europepmc   +1 more source

Bioanalytical method development and validation for determination of olutasidenib and its application to pharmacokinetic studies. [PDF]

RSC Adv
Nimmakayala MR, Rangamuni K, Surendra J, Prakash JM, Kolli D.   +4 more
europepmc   +1 more source

Double Strike in Chronic Lymphocytic Leukemia-The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice. [PDF]

Int J Mol Sci
Zygmunciak P, Dancewicz H, Stróżna K, Błażowska O, Bieliński K, Robak T, Puła B.   +6 more
europepmc   +1 more source

Ibrutinib enhances the bias of T cell responses towards staphylococcal superantigens sustaining inflammation in chronic lymphocytic leukaemia. [PDF]

Front Immunol
Tantoush F, Allsup D, Naylor-Adamson L, Voncken F, Caserta S.   +4 more
europepmc   +1 more source